Recent Updates
Recently added Catalysts
CON Positive Sentiment

Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Concentra has appointed Dr. Jill Rosenthal as Chief Medical Officer, effective January 1, 2027. Dr. Rosenthal, who has previously held leadership roles at Concentra, will oversee the company's national clinical strategy and physician leadership. Her extensive experience in occupational medicine positions her to drive clinical innovation within the organization.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Jill Rosenthal is a nationally recognized leader in occupational medicine.
  • Her appointment is expected to advance clinical innovation at Concentra.
  • She has a history of leadership within the organization.

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Concentra® (NYSE: CON), the nation's leader in occupational medicine, today announced that nationally recognized occupational medicine leader Jill Rosenthal, MD, MPH, will join the company Sept. 1 and assume the role of chief medical officer, effective Jan. 1, 2027. Returning to the organization where she previously served in physician leadership roles, including area medical director, Dr. Rosenthal will lead Concentra's national clinical strategy, physician leadership,

Frequently Asked Questions

Who is the new Chief Medical Officer of Concentra?

Dr. Jill Rosenthal has been appointed as the new Chief Medical Officer.

When will Dr. Rosenthal assume her role at Concentra?

Dr. Rosenthal will assume her role as CMO effective January 1, 2027.

What is Dr. Rosenthal's background?

Dr. Rosenthal is a nationally recognized leader in occupational medicine.

What will Dr. Rosenthal lead at Concentra?

She will lead Concentra's national clinical strategy and physician leadership.

ShareAdd on Google
Tags: CON Viatris Investor Conferences Healthcare Concentra Jill Rosenthal occupational medicine clinical strategy healthcare leadership
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$158M liquidity · $0M/mo burn
Low dilution risk